BioSpace News Archive

Altamira Therapeutics Ltd., a company dedicated to developing therapeutics that address important unmet medical needs, announced that it will host an Investor and Business Update Call on Monday, December 11, 2023, 8:30 a.m. ET.

NVIGEN, a leader in providing modern nanoparticle health care solutions, is poised to unveil its groundbreaking technology, NVIGEN X®-Precision Medicine Biomarker Profiling, at the San Antonio Breast Cancer Symposium from December 5 to 9.

Applied DNA Sciences, Inc. today announced that it will release its fourth quarter and full year financial results 2023 ended September 30, 2023, on Thursday, December 7, 2023, after the market close.

G1 Therapeutics, Inc. today announced the presentation of new data describing the long-term positive survival impact of previous treatment with trilaciclib and cytotoxic chemotherapy (gemcitabine/carboplatin; GCb) in patients with metastatic triple negative breast cancer (mTNBC) who participated in G1’s Phase 2 trial (NCT02978716).

BioInvent International today presents the first clinical data from a Phase 1/2a trial of its second FcyRIIB-blocking antibody BI-1607.

Exactech announced its subsidiary, BlueOrtho, has received 510(k) clearance from the Food and Drug Administration for ExactechGPS® Ankle, the world’s first surgical navigation system for total ankle arthroplasty (TAA).

Ceremorphic Life Sciences CEO Venkat Mattela delivered the keynote at today’s AI Driven Drug Discovery Summit in Boston MA, where he demonstrated the company’s new BioCompDiscoverX supercomputing platform.

First Light Diagnostics announced that the US Food and Drug Administration (FDA) has cleared its SensiTox® B. anthracis Toxin Test to be marketed in the U.S.

Vetter, a leading globally operating Contract Development and Manufacturing Organization (CDMO), has joined the Science Based Targets Initiative (SBTi) membership group as of November 2023.

The global precision oncology market size was estimated to grow from USD 100.06 billion in 2022 and is valued to soar USD 258.35 billion by 2032, at an expanding CAGR of 9.9% between 2023 and 2032.